Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

NGS Profile and the Mathematical Prediction Model for Venetoclax Combination Therapy in HM-Screen-Japan 02 Study

Tomoaki Ueda, Kentaro Fukushima, Naoki Hosen, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Kensuke Usuki, Naoto Takahashi, Naoko Hosono, Takahiro Yamauchi, Takeshi Kondo, Kazuhito Yamamoto, Junya Kuroda, Yosuke Minami

Blood (2023) 142 (Supplement 1): 5761.

https://doi.org/10.1182/blood-2023-180339

Published: 2023

Journal Articles

Lower-Initiating Dose of Bosutinib for Resistant or Intolerant to Prior Therapy Chronic Myeloid Leukemia Patients (BOGI trial): A Single-Arm, Multicenter, Phase II Trial

Hiroshi Ureshino, Naoto Takahashi, Takayuki Ikezoe, Ayako Takamori, Atsushi Kawaguchi, Tatsuo Ichinohe, Shinya Kimura

Blood (2023) 142 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2023-174594

Published: 2023

Journal Articles

The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey

Takeshi Kondo, Eri Matsuki, Tomoiku Takaku, Masaya Okada, Kazunori Murai, Chikashi Yoshida, Naoki Watanabe, Naoto Takahashi, Shinya Kimura, Itaru Matsumura

Blood (2023) 142 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2023-174169

Published: 2023

Journal Articles

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, Jorge Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Susanne Saussele, Francois Mahon, Tim H. Brümmendorf, Shruti Kapoor, Tracey McCulloch, Peter Schuld, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 6388.

https://doi.org/10.1182/blood-2023-186773

Published: 2023

Journal Articles

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Naoko Hosono, Takahiro Yamauchi, Chi Sung-Gi, Hironori Arai, Kentaro Fukushima, Daisuke Ikeda, Satoshi Iyama, Akihiko Gotoh, Takayuki Ikezoe, Chikashi Yoshida, Goichi Yoshimoto, Junya Kanda, Naoto Takahashi, Emiko Sakaida, Kensuke Usuki, Yosuke Minami

Blood (2023) 142 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2023-184546

Published: 2023

Journal Articles

Multiple Myeloma with 1q Gain/Amplification Shows Reduced CD38 Expression Via IL-6R Overexpression

Wataru Kuroki, Akihiro Kitadate, Masahiro Yamada, Sayaka Iwama, Yuto Takahashi, Yuki Fujioka, Takahiro Kobayashi, Sho Ikeda, Kentaro Narita, Kosei Matsue, Naoto Takahashi

Blood (2023) 142 (Supplement 1): 637.

https://doi.org/10.1182/blood-2023-173494

Published: 2023

Journal Articles

Tumor Suppressive Mir-7 Targeting PSME3 Improves the Efficacy of Histone Deacetylases Inhibitors in Multiple Myeloma

Masahiro Yamada, Sho Ikeda, Wataru Kuroki, Sayaka Iwama, Yuto Takahashi, Akihiro Kitadate, Fumito Abe, Hiroyuki Tagawa, Naoto Takahashi

Blood (2023) 142 (Supplement 1): 6592.

https://doi.org/10.1182/blood-2023-173475

Published: 2023

Journal Articles

The Real-World Outcomes of Ponatinib in 724 Patients with CML and Ph + ALL : A Post-Marketing Surveillance Study with a Special Interest in Arterial Occlusive Events in Japan

Naoto Takahashi, Takeshi Kondo, Yuji Ikari, Yoshihiro Fukumoto, Kiyohiko Hatake, Akira Masunari, Seiji Nishibayashi, Akiko Kageyama, Yasuhiko Fukuta, Arinobu Tojo

Blood (2023) 142 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2023-174324

Published: 2023

Journal Articles

Mechanism of Late Recurrences of Chronic Myeloid Leukemia after Discontinuation of TKI Therapy: BCR::ABL1 Ins35bp Loss-of-Function Splicing Mutation and Regulatory T Cells

Yuki Fujioka, Junichiro Yuda, Naoto Takahashi

Blood (2023) 142 (Supplement 1): 6344.

https://doi.org/10.1182/blood-2023-185710

Published: 2023

Journal Articles

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin–transferrin receptor 1 axis

Blood (2023) 142 (4): 352–364.

https://doi.org/10.1182/blood.2022018597

Published: 2023

Includes: Supplemental data

Journal Articles

ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Timothy Hughes, Jorge E. Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Shruti Kapoor, Sophie Ifrah, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6767–6768.

https://doi.org/10.1182/blood-2022-162249

Published: 2022

Journal Articles

STAT3 Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma

Yuto Takahashi, Akihiro Kitadate, Sho Ikeda, Sayaka Iwama, Ko Abe, Hiroyuki Tagawa, Hideki Wakui, Naoto Takahashi

Blood (2022) 140 (Supplement 1): 5971–5972.

https://doi.org/10.1182/blood-2022-165113

Published: 2022

Journal Articles

Hypoxia-Induced Oxidative Stress Promotes Proteasome Inhibitor Resistance Via Upregulation of Heme Oxygenase-1 in Multiple Myeloma

Ko Abe, Sho Ikeda, Miho Nara, Akihiro Kitadate, Hiroyuki Tagawa, Naoto Takahashi

Blood (2022) 140 (Supplement 1): 9974–9975.

https://doi.org/10.1182/blood-2022-159825

Published: 2022

Journal Articles

Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey

Zack Pemberton-Whiteley, Jorge E. Cortes, Joannie Clements, Cristina Ruiz, Delphine Rea, Lisa Machado, Fabian Lang, Naoto Takahashi, Nigel Deekes, Sung-Ho Moon, Andrew Grigg, Merula Steagall, Cornelia Borowczak, Virginia Pilipovic, Pauline Frank, Cristina Constantinescu, Carla Boquimpani

Blood (2021) 138 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2021-147739

Published: 2021

Journal Articles

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2021-149425

Published: 2021

Journal Articles

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Blood (2021) 138 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2021-149801

Published: 2021

Journal Articles

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2021-148492

Published: 2021

Journal Articles

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2021-149960

Published: 2021

Journal Articles

Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study

Takaaki Ono, Masayuki Hino, Itaru Matsumura, Shin Fujisawa, Kenichi Ishizawa, Emiko Sakaida, Naohiro Sekiguchi, Chiho Ono, Mana Aizawa, Yusuke Tanetsugu, Yuichiro Koide, Naoto Takahashi

Blood (2021) 138 (Supplement 1): 2557.

https://doi.org/10.1182/blood-2021-145164

Published: 2021

Journal Articles

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2021-146796

Published: 2021

NARROW

NGS Profile and the Mathematical Prediction Model for Venetoclax Combination Therapy in HM-Screen-Japan 02 Study

Lower-Initiating Dose of Bosutinib for Resistant or Intolerant to Prior Therapy Chronic Myeloid Leukemia Patients (BOGI trial): A Single-Arm, Multicenter, Phase II Trial

The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Multiple Myeloma with 1q Gain/Amplification Shows Reduced CD38 Expression Via IL-6R Overexpression

Tumor Suppressive Mir-7 Targeting PSME3 Improves the Efficacy of Histone Deacetylases Inhibitors in Multiple Myeloma

The Real-World Outcomes of Ponatinib in 724 Patients with CML and Ph + ALL : A Post-Marketing Surveillance Study with a Special Interest in Arterial Occlusive Events in Japan

Mechanism of Late Recurrences of Chronic Myeloid Leukemia after Discontinuation of TKI Therapy: BCR::ABL1 Ins35bp Loss-of-Function Splicing Mutation and Regulatory T Cells

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin–transferrin receptor 1 axis

ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

STAT3 Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma

Hypoxia-Induced Oxidative Stress Promotes Proteasome Inhibitor Resistance Via Upregulation of Heme Oxygenase-1 in Multiple Myeloma

Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only